Bio-Rad Laboratories, Inc.  

(Public, NYSE:BIO.B)   Watch this stock  
Find more results for BIO.B
126.80
+9.45 (8.05%)
Feb 27 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 125.58 - 126.80
52 week 108.79 - 133.99
Open 125.58
Vol / Avg. 612.00/54.00
Mkt cap 3.68B
P/E 41.59
Div/yield     -
EPS 3.05
Shares 5.10M
Beta 1.28
Inst. own 364%
Feb 26, 2015
Q4 2014 Bio-Rad Laboratories Inc Earnings Call
Feb 26, 2015
Q4 2014 Bio-Rad Laboratories Inc Earnings Release
Feb 11, 2015
Bio-Rad Laboratories Inc at Leerink Global Healthcare Conference
Jan 14, 2015
Bio-Rad Laboratories Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 6.53% 4.08%
Operating margin 8.46% 6.90%
EBITD margin - 13.79%
Return on average assets 4.65% 2.64%
Return on average equity 7.18% 4.06%
Employees 7,750 -
CDP Score - -

Address

1000 ALFRED NOBEL DR
HERCULES, CA 94547
United States - Map
+1-510-7247000 (Phone)
+1-510-7415815 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Bio-Rad Laboratories, Inc. (Bio-Rad) manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. Bio-Rad operates in two segments: Life Science and Clinical Diagnostics. The Company�s Life Science segment is engaged in the discovery and creation of tools to answer biological questions. It markets, develops, manufactures and markets a range of more than 5,000 reagents, apparatus and laboratory instruments. Its Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and quality controls that serve clinical laboratories in the global diagnostics market. The Company has direct distribution channels in over 35 countries outside the United States through subsidiaries.

Officers and directors

Norman D. Schwartz Chairman of the Board, President, Chief Executive Officer
Age: 64
Bio & Compensation  - Reuters
Christine A. Tsingos Chief Financial Officer, Executive Vice President
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John P Goetz Chief Operating Officer
Age: 64
Bio & Compensation  - Reuters
Shawn M. Soderberg Executive Vice President, General Counsel, Secretary
Age: 53
Bio & Compensation  - Reuters
Shannon Hall Executive Vice President, President, Life Science Group
Bio & Compensation  - Reuters
John Hertia Executive Vice President, President, Clinical Diagnostics Group
Bio & Compensation  - Reuters
Giovanni Magni Executive Vice President, International Sales Manager
Age: 57
Bio & Compensation  - Reuters
Ronald W. Hutton Vice President, Treasurer
Age: 56
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Joel McComb Director
Age: 49
Bio & Compensation  - Reuters
Alice N. Schwartz Director
Age: 87
Bio & Compensation  - Reuters